FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.
The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback